| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041566309 |
| P356 | DOI | 10.1111/J.1523-1755.2005.00185.X |
| P698 | PubMed publication ID | 15698460 |
| P50 | author | Justin Albert | Q79190038 |
| Tadao Akizawa | Q92774606 | ||
| Friedrich Port | Q95277507 | ||
| Ronald Pisoni | Q114400190 | ||
| Takashi Akiba | Q126120186 | ||
| P2093 | author name string | Eric W Young | |
| Kiyoshi Kurokawa | |||
| Jürgen Bommer | |||
| David A Goodkin | |||
| Sudtida Satayathum | |||
| Luis Piera | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1179-1187 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study | |
| P478 | volume | 67 |
| Q42727652 | A Japanese approach for CKD-MBD |
| Q28552810 | A New Data Analysis System to Quantify Associations between Biochemical Parameters of Chronic Kidney Disease-Mineral Bone Disease |
| Q37552700 | A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease |
| Q35934749 | A case report of sevelamer-associated recto-sigmoid ulcers |
| Q35573634 | A new paradigm for the treatment of secondary hyperparathyroidism |
| Q37702270 | A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis |
| Q40681507 | Achievement of guideline targets in elderly patients on hemodialysis: a multicenter study |
| Q36976908 | Achievement of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative: recommended serum calcium, phosphate and parathyroid hormone values with parathyroidectomy in patients with secondary hyperparathyroidism |
| Q33890218 | Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients |
| Q26827655 | Arterial calcification in chronic kidney disease: key roles for calcium and phosphate |
| Q27001011 | Artificial receptors for the recognition of phosphorylated molecules |
| Q40318370 | Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. |
| Q34135288 | Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients |
| Q36371052 | Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes |
| Q37075732 | Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients |
| Q36044367 | Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease |
| Q34694396 | Bone health and vascular calcification relationships in chronic kidney disease |
| Q37671125 | Bone mineral metabolism and subsequent hospitalization with poor quality of life in dialysis patients |
| Q37034270 | CKD-MBD: impact on management of kidney disease. |
| Q37182739 | Calcimimetics in chronic kidney disease: evidence, opportunities and challenges |
| Q36406652 | Calcium abnormalities of dialysis patients. |
| Q50573885 | Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. |
| Q30473207 | Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study |
| Q86478416 | Causes of death in peritoneal dialysis patients with different kidney diseases and comorbidities: a retrospective clinical analysis in a Chinese center |
| Q37324775 | Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients |
| Q87041760 | Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium |
| Q37054196 | Characteristics of the clinical practice patterns of hemodialysis in Japan in consideration of DOPPS and the NKF/DOQI guidelines |
| Q37123151 | Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients |
| Q36900943 | Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial |
| Q91722317 | Citric-acid dialysate improves the calcification propensity of hemodialysis patients: A multicenter prospective randomized cross-over trial |
| Q35030613 | Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. |
| Q37535964 | Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride |
| Q40318270 | Clinical significance of parathyroid intervention on CKD-MBD management. |
| Q57218915 | Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients |
| Q36193436 | Combined alkaline phosphatase and phosphorus levels as a predictor of mortality in maintenance hemodialysis patients |
| Q34497220 | Comparative Effectiveness of Calcium-Containing Phosphate Binders in Incident U.S. Dialysis Patients |
| Q41542599 | Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials. |
| Q34725113 | Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis |
| Q36497902 | Con: Phosphate binders in chronic kidney disease |
| Q36843462 | Consistent control of mineral and bone disorder in incident hemodialysis patients |
| Q50531502 | Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study. |
| Q36936601 | Correlates of parathyroid hormone concentration in hemodialysis patients |
| Q36842440 | Cost-effectiveness of frequent in-center hemodialysis |
| Q40318011 | Current status of parathyroidectomy for secondary hyperparathyroidism in Japan |
| Q33847932 | Detection of pulmonary calcification in haemodialised patients by whole-body scintigraphy and the impact of the calcification to parameters of spirometry |
| Q40501573 | Development and Validation of a Novel Laboratory-Specific Correction Equation for Total Serum Calcium and Its Association With Mortality Among Hemodialysis Patients |
| Q36300956 | Development of a new risk model for predicting cardiovascular events among hemodialysis patients: Population-based hemodialysis patients from the Japan Dialysis Outcome and Practice Patterns Study (J-DOPPS). |
| Q36911708 | Diabetic nephropathy in the elderly. |
| Q41863686 | Diagnostic Workup for Disorders of Bone and Mineral Metabolism in Patients with Chronic Kidney Disease in the Era of KDIGO Guidelines |
| Q99558419 | Dialysate Calcium: A Lot More Than 'Set It and Forget It' |
| Q36267767 | Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients |
| Q34910006 | Direct effects of phosphate on vascular cell function |
| Q79817432 | Direct injection of calcitriol or its analog into hyperplastic parathyroid glands induces apoptosis of parathyroid cells |
| Q79761766 | Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism |
| Q37740460 | Discrepancies in Clinic and Ambulatory Blood Pressure in Korean Chronic Kidney Disease Patients |
| Q57222056 | Does sevelamer have greater skeletal benefit than calcium carbonate in children with secondary hyperparathyroidism? |
| Q42856989 | Economic Analysis of Cinacalcet in Combination With Low-Dose Vitamin D Versus Flexible-Dose Vitamin D in Treating Secondary Hyperparathyroidism in Hemodialysis Patients |
| Q42678184 | Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy |
| Q35189516 | Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study |
| Q39237776 | Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease |
| Q96132965 | Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis |
| Q49279657 | Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients |
| Q86780536 | Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy |
| Q87748892 | Efficacy and safety of eldecalcitol, a new active vitamin D3 analog, in the bone metabolism of postmenopausal women receiving maintenance hemodialysis |
| Q36736647 | Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis |
| Q35573639 | Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin d sterols in dialysis patients |
| Q34755816 | Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease |
| Q37613856 | Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia |
| Q44705332 | Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease |
| Q92081595 | Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life" |
| Q39387561 | FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study |
| Q44716347 | Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease |
| Q36443233 | Habitual physical activity measured by accelerometer and survival in maintenance hemodialysis patients |
| Q35124228 | Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management? |
| Q36965339 | Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients |
| Q37607448 | High Serum Alkaline Phosphatase, Hypercalcaemia, Race, and Mortality in South African Maintenance Haemodialysis Patients. |
| Q81441194 | High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death |
| Q36516021 | High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease |
| Q55528210 | Higher dialysate calcium concentration is associated with incident myocardial infarction among diabetic patients with low bone turnover: a longitudinal study. |
| Q33873467 | Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients |
| Q36061887 | Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis |
| Q28081229 | Hyperphosphatemia. The hidden killer in chronic kidney disease |
| Q38925728 | Hypophosphatemia: nutritional status, body composition, and mortality in hemodialysis patients. |
| Q36736670 | Identifying best practices in dialysis care: results of cognitive interviews and a national survey of dialysis providers |
| Q36195418 | Impact of Dialysate Calcium Concentration on Clinical Outcomes in Incident Hemodialysis Patients |
| Q34459406 | Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study |
| Q40090142 | Impact of nutritional index on the association between phosphorus concentrations and mortality in haemodialysis patients: a cohort study from dialysis outcomes and practice pattern study in Japan. |
| Q35051572 | Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era. |
| Q51789429 | Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. |
| Q36765955 | Inflammation and anaemia as predictors of cardiovascular mortality in hemodialysis patients |
| Q49852706 | Influence of Carnicor, Venofer, and Sevelamer on the levels of genotoxic damage in end-stage renal disease patients |
| Q38671509 | Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. |
| Q34456584 | Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223. |
| Q98178842 | International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes and Practice Patterns Study |
| Q36669039 | Introduction: improving outcomes in chronic kidney disease. |
| Q34366087 | Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism? |
| Q27011288 | Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis |
| Q79424328 | K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? |
| Q28079982 | Lanthanum carbonate: safety data after 10 years |
| Q64911767 | Long-term effects on PTH and mineral metabolism of 1.25 versus 1.75 mmol/L dialysate calcium in peritoneal dialysis patients: a meta-analysis. |
| Q42369658 | Low serum phosphate as an independent predictor of increased infection-related mortality in dialysis patients: A prospective multicenter cohort study |
| Q39023147 | Management of phosphorus load in CKD patients. |
| Q37547201 | Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease. |
| Q36443751 | Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials |
| Q36142207 | Mechanisms and clinical consequences of vascular calcification |
| Q34672695 | Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study |
| Q92122895 | Mineral and bone disorder and management in the China Dialysis Outcomes and Practice Patterns Study |
| Q30418571 | Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease |
| Q36994038 | Mineral metabolic abnormalities and mortality in dialysis patients |
| Q37378445 | Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. |
| Q34550213 | Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients. |
| Q79478108 | Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients |
| Q33625482 | Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients |
| Q79190034 | Mortality risk among hemodialysis patients receiving different vitamin D analogs |
| Q30429870 | Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD |
| Q30433029 | Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease |
| Q47758125 | Parathyroid hormone is related to QT interval independent of serum calcium in patients with coronary artery disease. |
| Q83223028 | Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism |
| Q34857892 | Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis |
| Q38824573 | Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease |
| Q34854318 | Pharmacology of the phosphate binder, lanthanum carbonate |
| Q33566596 | Phosphate and cardiovascular disease |
| Q55507997 | Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. |
| Q36279054 | Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS |
| Q24244049 | Phosphate binders for preventing and treating bone disease in chronic kidney disease patients |
| Q35287803 | Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells |
| Q37492019 | Phosphate: an old bone molecule but new cardiovascular risk factor |
| Q34907022 | Phosphorus binders and survival on hemodialysis |
| Q36796740 | Pitfalls of measuring total blood calcium in patients with CKD |
| Q40171095 | Positive association of vigorous and moderate physical activity volumes with skeletal muscle mass but not bone density or metabolism markers in hemodialysis patients |
| Q35007369 | Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis |
| Q34858005 | Prescribed dietary phosphate restriction and survival among hemodialysis patients |
| Q37551497 | Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders |
| Q37015581 | Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India |
| Q37672557 | Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes |
| Q26849298 | Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease |
| Q34828835 | Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study |
| Q35574573 | Recurrent renal hyperparathyroidism due to parathyromatosis |
| Q42371213 | Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. |
| Q26825788 | Regulatory circuits controlling vascular cell calcification |
| Q35657914 | Risk Score to Predict 1-Year Mortality after Haemodialysis Initiation in Patients with Stage 5 Chronic Kidney Disease under Predialysis Nephrology Care |
| Q33671574 | Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012. |
| Q84976574 | Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients |
| Q35023526 | Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population |
| Q34611536 | Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). |
| Q36880126 | Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. |
| Q37803240 | Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III – V) |
| Q37052751 | Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis |
| Q36443804 | Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. |
| Q37032561 | Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis |
| Q55436115 | Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort. |
| Q37330326 | Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl |
| Q89944617 | Sirtuin-1 and Its Relevance in Vascular Calcification |
| Q37729792 | Stirring the Pot: Can Dietary Modification Alleviate the Burden of CKD? |
| Q37402493 | Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis |
| Q30316084 | Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons |
| Q46122319 | Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients |
| Q36938843 | Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden |
| Q33454103 | Testing the Feasibility and Usability of a Novel Smartphone-Based Self-Management Support System for Dialysis Patients: A Pilot Study |
| Q33702417 | The DOPPS Practice Monitor for US Dialysis Care: PTH Levels and Management of Mineral and Bone Disorder in US Hemodialysis Patients |
| Q64890295 | The Effect of Ketoanalogues on Chronic Kidney Disease Deterioration: A Meta-Analysis. |
| Q35573642 | The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. |
| Q36466078 | The association between mortality and abdominal aortic calcification and relation between its progression and serum calcium concentration in chronic hemodialysis patients. |
| Q37354867 | The association between parathyroid hormone and mortality in dialysis patients is modified by wasting |
| Q45996029 | The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. |
| Q92244579 | The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients |
| Q37734160 | The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study |
| Q34293730 | The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis |
| Q38793054 | The role of phosphate in kidney disease |
| Q34533678 | The role of serum magnesium and calcium on the association between adiponectin levels and all-cause mortality in end-stage renal disease patients |
| Q83683568 | Total parathyroidectomy without autotransplantation in the surgical treatment of secondary hyperparathyroidism of chronic kidney disease |
| Q39374348 | Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide |
| Q35790561 | Uncorrected and Albumin-Corrected Calcium, Phosphorus, and Mortality in Patients Undergoing Maintenance Dialysis |
| Q37199788 | Use of nicotinamide to treat hyperphosphatemia in dialysis patients |
| Q64288909 | Use of phosphate binders in end-stage renal disease: An experience from a secondary care hospital in United Arab Emirates |
| Q35891563 | Usefulness and feasibility of measuring ionized calcium in haemodialysis patients |
| Q80101278 | Vascular calcification: contribution of parathyroid hormone in renal failure |
| Q34025119 | Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease |
| Q42092825 | Vitamin D and kidney disease |
| Q24240439 | Vitamin D compounds for people with chronic kidney disease not requiring dialysis |
| Q24240582 | Vitamin D compounds for people with chronic kidney disease requiring dialysis |
| Q34997739 | Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies |
| Q37737597 | Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug? |
| Q37642219 | Whole blood versus serum ionized calcium concentrations in dialysis patients |
| Q87999931 | [Decline in renal function in old age : Part of physiological aging versus age-related disease] |
Search more.